Photodynamic technology specialist Photocure has published data on a retrospective study showing Hexvix (hexaminolevulinate) fluorescent-guided bladder resection improves overall survival and recurrence-free survival, compared to resection performed with standard white light. 29 January 2015
US biotech firm Dendreon said yesterday that it would be extending the bid deadline for interested parties to submit qualified bids to participate in an auction for the company’s assets from 5pm Eastern Time on January 27 to the same time on January 29 to continue discussions with potential bidders. 28 January 2015
USA-based Amgen, the world’s leading independent biotech firm, and its subsidiary Onyx Pharmaceuticals have submitted a supplemental New Drug Application to the US Food and Drug Administration for Kyprolis (carfilzomib). 28 January 2015
French biopharma company Hybrigenics says it has extended its partnership with France’s leading independent pharma company Servier to discover new drugs which inhibit Ubiquitin-Specific Proteases (USPs). 27 January 2015
US clinical-stage biopharma company Kite Pharma, focused on developing engineered autologous T cell therapy (eACT) products for the treatment of cancer, has expanded its agreement with Tel Aviv Sourasky Medical Center to research and develop novel approaches to chimeric antigen receptor (CAR) T cell therapy. 26 January 2015
Oncology specialist Array Biopharma has reached an agreement with Swiss drug major Novartis to acquire the worldwide rights to encorafenib (LGX818). 23 January 2015
The German Federal Joint Committee has confirmed the ‘considerable’ additional benefit of Japanese drug major Eisai’s Halaven (eribulin) for breast cancer. 23 January 2015
The value of the colorectal cancer (CRC) therapeutics market will increase moderately, from $8.3 billion in 2013 to $9.4 billion by 2020, representing a compound annual growth rate (CAGR) of 1.8%, new research forecasts. 22 January 2015
The German Institute for Quality and Efficiency in Health Care (IQWiG) has reviewed a number of dossiers to assess whether the drugs offer patients an added benefit over one of the appropriate comparator therapies. 22 January 2015
Investment company Syncona and UCL Business, the wholly-owned technology transfer company of University College London, have launched Autolus Limited, a biopharmaceutical company focused on the development and commercialization of next-generation engineered T-cell therapies for hematological and solid tumors 22 January 2015
USA-based Ariad Pharmaceuticals today revealed that the European Commission has endorsed the final opinion adopted by the Committee for Medicinal Products for Human Use (CHMP) on Iclusig (ponatinib) following recommendations made by the Pharmacovigilance Risk Assessment Committee (PRAC). 20 January 2015
Oncology and immunology specialist Tiziana Life Sciences has exclusively licensed milciclib from Nerviano Medical Sciences Group, an Italian cancer therapy company. 20 January 2015
Taiwan's PharmaEngine says that the additional analyses from the global Phase III NAPOLI-1 study of MM-398 (PEP02, liposome irinotecan injection) in metastatic pancreatic cancer were presented at the American Society of Clinical Oncology 2015 Gastrointestinal Cancers Symposium (ASCO GI) confirming earlier positive findings. 20 January 2015
Privately-held Solasia Pharma and fellow Japanese drugmaker Meiji Seika Pharma have entered into a license agreement for the development and commercialization of darinaparsin (intravenous formulation) in Japan. 19 January 2015
The UK’s National Audit Office has published a report, Progress in improving cancer services and outcomes in England, which confirms that English cancer patients’ health outcomes and survival rates are poorer than their European counterparts due to access to life-saving medicines. 16 January 2015
Canada’s OncoGenex Pharmaceuticals says that the AFFINITY trial is continuing as planned based upon completion of the interim futility analysis and the recommendation of the Independent Data Monitoring Committee (IDMC). 16 January 2015
France-based genome engineering specialist Cellectis has entered into an exclusive license agreement with the USA’s Ohio State University, through the Ohio State Innovation Foundation. 16 January 2015
USA-based Amgen, the world’s leading independent biotech firm, says that Phase II and Phase III studies have demonstrated no differences in quality of life between the chemo combination FOLFOX regimens with or without Vectibix (panitumumab). 16 January 2015
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Pfizer released positive top line results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide). 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
The European Medicines Agency (EMA) has accepted for review the Marketing Authorization Applications for AVT03, a proposed biosimilar candidate to the Prolia and Xgeva (denosumab), submitted by Germany’s STADA Arzneimittel. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Bayer has entered into a collaboration with MOMA Therapeutics to develop a small molecule oncology program using the latter’s proprietary KNOMATIC platform. 9 October 2024
Genor Biopharma has announced plans for a significant merger with Edding Group, marking one of the first reverse takeovers involving a Hong Kong-listed biopharma company. 8 October 2024
China-headquartered clinical-stage biotech MediLink Therapeutics has announced a global clinical trial collaboration and supply agreement with US major Amgen. 8 October 2024
Germany’s Eckert & Ziegler, a specialist in radioisotopes for medical, scientific and industrial applications, has announced a global clinical supply agreement with GlyTherix, an Australian targeted radiotherapy firm specializing in developing antibody radiopharmaceuticals for solid tumors. 8 October 2024
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo Pharmaceuticals. 8 October 2024
Daejeon-based Orum Therapeutics, a specialist in degrader-antibody conjugates (DAC), has filed for an initial public offering (IPO) on South Korea's Kosdaq market. 7 October 2024
Mosaic Therapeutics, a UK-based oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, has announced the appointment of Barry Davies as chief scientific officer. 7 October 2024